Back to News
Market Impact: 0.34
UCB's CIMZIA Receives FDA Breakthrough Therapy Designation In Pregnant Women With APS
Source: Nasdaq
Healthcare & BiotechProduct Launches
UCB's CIMZIA (certolizumab pegol) received FDA Breakthrough Therapy Designation for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with lupus-positive antiphospholipid syndrome. The designation can accelerate development and regulatory review for this potential new indication, strengthening CIMZIA's clinical and commercial outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
UCB0.85
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine